Alligator Bioscience is a clinical-stage biotech company developing agonistic antibody-based pharmaceuticals for tumour-directed immunotherapy of cancer. Our lead asset, mitazalimab, a second generation CD40 agonist, is in phase 2 clinical development in first line pancreatic cancer in combination with chemotherapy. Interim data show promising efficacy and safety profiles. Mitazalimab has orphan designation with FDA and EMA. Top-line phase 2 data are expected early Q1 2024. In addition, we are developing bispecific CD40xTAA agonists based on our proprietary Neo-X-prime™ concept and proprietary bsAb format, RUBY™. The first drug candidate, ATOR-4066, targeting CD40xCEA has recently entered IND-enabling studies.